Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

‘Better Compounds Faster’ – The Development and Exploitation of a Desktop Predictive Chemistry Toolkit

John Cumming, Global Programme Manager for Predictive Chemistry, AstraZeneca R&D, speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
AstraZeneca Appoints Pascal Soriot CEO
Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
Tuesday, August 28, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
The definitive collaboration agreement will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan.
Thursday, August 13, 2009
IRESSA Receives Marketing Authorization for the Treatment of Non-Small Cell Lung Cancer in Europe
European Commission grants marketing authorization for the oral anti-cancer drug.
Tuesday, July 07, 2009
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
BioDuro and AstraZeneca announced that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.
Friday, March 27, 2009
AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights.
Tuesday, February 10, 2009
AstraZeneca and MAP Collaborate for Development and Commercialization of Unit Dose Budesonide
Unit Dose Budesonide is being developed as a potential treatment for pediatric asthma and is currently in Phase III clinical development.
Monday, December 22, 2008
AstraZeneca Announces Partnership with Singapore Institutions to Develop Anti-Cancer Compounds
The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients.
Tuesday, August 19, 2008
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
Wednesday, July 02, 2008
AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
AstraZeneca has submitted two separate supplemental New Drug Applications to the US FDA for once-daily Seroquel XR™ Extended-Release Tablets.
Thursday, January 03, 2008
Scientific News
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
New Clue to How Cancer Causes Organ Failure
New findings from a research group at Uppsala University show that the neutrophil, a type of blood cell, plays an important role in the process of induced organ failure.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Seashells to Deliver New Drugs and Vaccines
Australian scientists have developed a protective seashell-inspired capsule to preserve the active biological ingredients needed to create new drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
New Type of Drug Can Target All Disease-causing Proteins
Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.
Laser Technique for Self-Assembly of Nanostructures
Researchers have developed a low-cost technique that holds promise for a range of scientific and technological applications.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters